Norucholic acid for PSC patients from prior trial
Part of Digestive system clinical trials.
This study tests a medication called norucholic acid for people with primary sclerosing cholangitis who already took part in an earlier trial of the same drug. It’s meant for those who either finished the previous study or stopped early because the drug wasn’t helping.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have primary sclerosing cholangitis (PSC).
- You took part in the earlier NUC-5/PSC trial and either finished the main part or stopped early because the drug wasn’t working.
- You did not stop the earlier trial because of side effects from the study drug.
- You do not have liver cirrhosis (scarring of the liver) or need a liver transplant.
- You do not drink heavily (more than 2 drinks per day for men, or more than 1 drink per day for women).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
This study tests an investigational drug called TAK-781 in healthy volunteers and in people with primary sclerosing cholangitis (PSC) who do not have cirrhosis. The study aims to see how the drug is processed by the body and whether it is safe.
This study tests a new medication called elafibranor for adults with primary sclerosing cholangitis (PSC), a chronic liver disease. It aims to see if elafibranor can safely help improve liver health when compared to no treatment.
This study tests whether a treatment made from mouth bacteria can help people with primary sclerosing cholangitis (PSC). It aims to see if it's safe and improves health.
This early study looks at how a statin (cholesterol-lowering medicine) affects people with primary sclerosing cholangitis (PSC) by measuring changes using multiple types of health data. It may help researchers understand which people benefit and how PSC biology changes with treatment.
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
Hear when a new Primary Sclerosing Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.